4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Nuvalent, Inc. (NUVL) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 234 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, NUVL reported $0M in revenue and ($425M) in net income.
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($414M) | ($280M) | ($150M) | ($86M) | — |
| Net Income | ($425M) | ($261M) | ($126M) | ($82M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($119M) | ($102M) | ($113M) | ($105M) | ($95M) | — |
| Net Income | ($109M) | ($119M) | ($122M) | ($100M) | ($85M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.4B | $1.1B | $732M | $482M | — |
| Total Liabilities | $164M | $72M | $32M | $20M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NUVL viewer.
About TickerBase · Data methodology & sources